Next Article in Journal
Clinicopathological Significances of Tumor–Stroma Ratio (TSR) in Colorectal Cancers: Prognostic Implication of TSR Compared to Hypoxia-Inducible Factor-1α Expression and Microvessel Density
Previous Article in Journal
The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging
Open AccessSystematic Review

The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review

1
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
2
Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada
3
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada
4
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON L8S 4L8, Canada
5
Department of Orthopedic Surgery, McMaster University, Hamilton, ON L8S 4L8, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(2), 1302-1313; https://doi.org/10.3390/curroncol28020124
Received: 16 February 2021 / Revised: 16 March 2021 / Accepted: 18 March 2021 / Published: 22 March 2021
Background: The role of denosumab in patients with resectable giant cell tumour of bone remains unclear. We asked the following research question: for patients (aged ≥ 12 years) with resectable giant cell tumour of bone, what are the benefits and harms of denosumab compared with no denosumab in terms of (1) facilitation of surgery (operative time, blood loss), (2) disease recurrence, (3) pain control, (4) disease stability, and (5) adverse effects (e.g., malignant transformation, osteonecrosis of jaw, atypical femur fracture)? One previous systematic review addressed only one outcome—disease recurrence. Therefore, we undertook this new systematic review to address the above five outcomes. Methods: MEDLINE, EMBASE, PubMed, and Cochrane Database of Systematic Reviews databases were searched on June 30, 2020. Results: This systematic review included one previous systematic review and five comparative studies. Due to poor quality, non-randomized studies fraught with selection bias, it is difficult to determine if a significant difference exists in the outcomes for surgical giant cell tumour of bone with perioperative denosumab. There were no reported cases of adverse effects from denosumab. Conclusion: To date, there is insufficient evidence to understand the value of denosumab in the perioperative setting in patients with giant cell tumour of bone. View Full-Text
Keywords: denosumab; giant cell tumour of bone; surgical outcomes; systematic review denosumab; giant cell tumour of bone; surgical outcomes; systematic review
Show Figures

Figure 1

MDPI and ACS Style

Gupta, A.; Durocher-Allen, L.; Popovic, S.; Tozer, R.; Yao, X.; Ghert, M. The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review. Curr. Oncol. 2021, 28, 1302-1313. https://doi.org/10.3390/curroncol28020124

AMA Style

Gupta A, Durocher-Allen L, Popovic S, Tozer R, Yao X, Ghert M. The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review. Current Oncology. 2021; 28(2):1302-1313. https://doi.org/10.3390/curroncol28020124

Chicago/Turabian Style

Gupta, Abha; Durocher-Allen, Lisa; Popovic, Snezana; Tozer, Richard; Yao, Xiaomei; Ghert, Michelle. 2021. "The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review" Curr. Oncol. 28, no. 2: 1302-1313. https://doi.org/10.3390/curroncol28020124

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop